Abstract Library

#427 Gastric Carcinoids: Prevalence in Europe and USA, and Rationale for Treatment with YF476, a Gastrin Receptor Antagonist

Introduction: Gastric carcinoids (GC) are tumors arising from enterochromaffin-like (ECL) cells in the gastric mucosa. Most are caused by hypergastrinaemia, which stimulates ECL-cell growth. YF476 is a potent, selective and orally active gastrin receptor antagonist in humans in vitro and in vivo. YF476 prevented and caused shrinkage of GC in animal models of the condition.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Boyce M,

Keywords: gastric carcinoids, ECL cells, YF476, OMP,

#406 YF476, a Gastrin Receptor Antagonist, Causes Regression of Tumors and Normalizes Serum Chromogranin A in Patients with Type 1 Gastric Carcinoids

Introduction: Chronic atrophic gastritis (CAG) results in achlorhydria, hypergastrinemia and, in some patients, gastric carcinoids (type 1 GCs). Type 1 GCs may become malignant and metastasize. Current treatments of type 1 GCs, such as polypectomy, somatostatin analogues and antrectomy, have their disadvantages. YF476 – a potent, selective, orally active and well-tolerated gastrin receptor antagonist in pre-clinical studies – prevented, as well as reduced, the number and size of gastric carcinoids and carcinomas in rodent models.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Fossmark R, Sørdal �, Jianu C, Qvigstad G, Boyce M,

Keywords: gastric carcinoids, gastrin, chromogranin A,